C WorldWide Group Holding A S decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,056,705 shares of the medical research company’s stock after selling 90,682 shares during the quarter. Thermo Fisher Scientific makes up approximately 7.6% of C WorldWide Group Holding A S’s portfolio, making the stock its 3rd largest position. C WorldWide Group Holding A S’s holdings in Thermo Fisher Scientific were worth $599,056,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. JJJ Advisors Inc. bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth $25,000. Ellevest Inc. grew its stake in shares of Thermo Fisher Scientific by 137.5% in the 2nd quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock worth $28,000 after acquiring an additional 55 shares in the last quarter. American National Bank bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth $29,000. Massey Quick Simon & CO. LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $30,000. Finally, Redhawk Wealth Advisors Inc. bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $31,000. Hedge funds and other institutional investors own 88.24% of the company’s stock.

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Robert W. Baird upped their target price on shares of Thermo Fisher Scientific from $305.00 to $319.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Credit Suisse Group reiterated a “buy” rating and issued a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Needham & Company LLC upped their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, ValuEngine downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $314.45.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,833 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $272.93, for a total transaction of $500,280.69. Following the sale, the director now directly owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the sale, the chief executive officer now directly owns 328,960 shares in the company, valued at $97,332,684.80. The disclosure for this sale can be found here. Insiders sold a total of 51,833 shares of company stock worth $15,299,095 over the last three months. 0.45% of the stock is owned by insiders.

Shares of NYSE:TMO traded up $1.11 during midday trading on Friday, reaching $294.65. The company had a trading volume of 787,876 shares, compared to its average volume of 1,323,858. The company’s 50 day moving average price is $290.18 and its 200 day moving average price is $283.40. The company has a current ratio of 1.80, a quick ratio of 1.23 and a debt-to-equity ratio of 0.56. The stock has a market cap of $117.34 billion, a P/E ratio of 26.50, a P/E/G ratio of 1.90 and a beta of 1.14. Thermo Fisher Scientific Inc. has a 52-week low of $208.34 and a 52-week high of $306.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion for the quarter, compared to the consensus estimate of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.62 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Tuesday, December 17th will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: What is the NASDAQ?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.